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Objective: There are limited data regarding the significance of elevated serum CA-125 level during IUI cycles, even though it is used widely 
during the initial evaluation of infertile patients. The aim of this study was to investigate the prognostic value of serum CA-125 levels during IUI 
cycles.
Methods: Among the patients with controlled ovarian stimulation and IUI cycles at Seoul National University Hospital from Jan 2005 through 
Dec 2009, 92 cases with no identified endometriotic lesion, ovarian tumor, salpingeal lesion, or uterine myoma were selected. To compare the 
clinical characteristics between the pregnancy group and the non-pregnancy group, the Mann-Whitney U test and Fisher’s exact test were used.
Results: The overall pregnancy rate was 18.5% (17/92). The pregnancy group showed a higher number of follicles 16 mm in diameter (p=0.036), 
endometrial thickness (p<0.001), ampules of gonadotropin (p=0.009), and higher body mass index (p=0.022) than the non-pregnancy group. 
No significant difference was observed in the serum CA-125 level or the proportion of patients with CA-125 exceeding 17 IU/mL between the 
two groups.
Conclusion: The prognostic value of serum CA-125 level among infertile patients with IUI cycles is considered limited.
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Introduction
IUI is a common procedure applicable in cases of cervical infertility, 
male factor infertility, anovulation, endometriosis with a healthy fal-
lopian tube, and unexplained infertility. Endometriosis, uterine myo-
mas, acute and chronic salpingitis, and pelvic inflammatory disease 
are female factors that are known to have a negative impact on the 
pregnancy rate during the IUI cycle [1-3]. Still, the mechanisms by 
which these factors affect the outcome of infertility treatment remain 
unclear. 
CA-125 is a high-molecular-weight glycoprotein that presents on 
the epithelium of the fallopian tubes, endometrium, endocervix, as 
well as other tissues of Müllerian origin [4,5]. Measurement and mon-
itoring of CA-125 level may be a simple and inexpensive test that can 
identify a subgroup of patients who are likely to have pelvic patholo-
gies such as endometriosis, uterine myomas, acute and chronic sal-
pingitis, ovarian tumors, and pelvic inflammatory disease, which are 
not detectable in the initial examination [5]. Little data is currently 
available regarding the cutoff values for screening for a uterine myo-
ma or an adnexal mass. Previous studies focused mainly on the de-
tection of endometriosis using the serum CA-125 level and a serum 
level of 17-35 U/mL has been reported to have sensitivities of 20-
94% and specificities of 77-92% in detection of endometriosis grade 
I/IV [6-9]. Hence we hypothesized that an elevation of the serum CA-
125 level may be linked to a lower pregnancy rate in IUI cycles. To our 
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knowledge, few studies have addressed the relationship between 
the serum CA-125 level and the outcome of IUI. In this study, we 
aimed to explore whether the serum CA-125 level differs according 
to the outcomes of IUI cycles.
Methods
Patients who had undergone controlled ovarian stimulation and IUI 
cycles at Seoul National University Hospital from January 2005 to De-
cember 2009 were selected. All couples had a duration of infertility 
of more than one year and were eligible for superovulation and IUI 
cycles. Cases with a physically or sonographically identifiable endo-
metriotic lesion, ovarian or salpingeal mass, or uterine myoma were 
excluded. Other pelvic abnormalities such as unilateral tubal obstruc-
tion or uterine anomaly were classified as female causes of infertility. 
Male factor infertility was defined by the World Health Organization 
criteria [10]. Serum CA-125 levels were measured on menstrual day 3 
with other steroid hormones as an initial evaluation of infertility us-
ing radioimmunoassay kit (Fujirebio Diagnostics, Malvern, PA, USA). 
Controlled ovarian stimulation (COS) was performed with urinary 
hMG (IVF-M®, LG Life Sciences, Seoul, Korea) and clomiphene citrate 
(Clomiphene®, Youngpoong Pharma, Seoul, Korea) in a dose of 150 
mg/day given from day 3 through day 7 of the menstrual cycle. A re-
combinant hCG (Ovidrel®, Serono, Geneva, Switzerland) in a dose of 
250 μg was given when either the leading follicle reached a mean di-
ameter of 18 mm or two or more follicles reached a diameter of 17 
mm. IUI was then performed 36 hours later. 
The luteal phase was supported by a daily application of 8% pro-
gesterone gel (Crinone®, Serono, Geneva, Switzerland), initially for 14 
days, starting on the day of the IUI, and continuing for another 6-8 
weeks in cases with pregnancy. Clinical pregnancy was defined by 
the presence of an intrauterine gestational sac with fetal heartbeats 
at 3 to 4 weeks after insemination.
Data were analyzed with SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA). 
Fisher’s exact test was used to compare proportions, and the Mann-
Whitney U test to compare means. A p-values less than 0.05 were 
considered statistically significant.
Results
The overall pregnancy rate was 18.5% (17/92). The mean age was 
33.2±3.1 years; the mean duration of infertility was 3.4±2.2 years, 
and the mean body mass index (BMI) was 22.0±5.1 kg/m
2. More 
than a third of the women (34.8%) had achieved a prior pregnancy. 
The infertility factors of the subjects were identified as unexplained 
(28.3%), female (62.0%), and male (17.4%) factors. The serum level of 
CA-125 ranged from 1.7 to 77.1 IU/mL in the study population. Among 
the pregnancy group and the non-pregnancy group, there was no 
significant difference in patient’s age, incidence of nulliparity, cause 
and duration of infertility. The mean BMI of the pregnancy group was 
significantly higher than that of the non-pregnancy group (23.7±4.0 
vs. 21.6±5.3, p=0.022). The pregnancy group showed a higher 
number of follicles with a diameter greater than 16 mm (p=0.036), 
greater endometrial thickness (p<0.001), and a greater number of 
gonadotropin ampoules (p=0.009). No significant differences were 
observed in the serum CA-125 levels and the percentage of patients 
with CA-125 exceeding 17 IU/mL between the two groups (Table 1).
Discussion
The association of the serum CA-125 level with the outcome of in 
vitro fertilization has been investigated in a number of studies and 
the results to date have been contradictory [11-15]. To our knowl-
edge, there have been no published studiesregarding serum CA-125 
levels before COS with an IUI cycle and pregnancy. Mild elevation of 
the serum CA-125 level before ovarian stimulation may reflect unde-
tected abnormal pelvic conditions such as endometriosis, uterine 
myomas, acute/chronic salpingitis, pelvic inflammatory disease, and 
ovarian tumors, all of which are known to affect fecundity [1,16,17]. 
The mechanisms of reduced fertility in minimal to mild endometrio-
sis, distal tubal disease, or adnexal lesion are unknown. In endometri-
Table 1. Patient characteristics according to the achievement of 
pregnancy
Parameters
Pregnancy
p-value
Yes (n=17) No (n=75)
Woman’s age (yr) 33.2±2.8 33.2±3.2 NS
Previous pregnancy  23.5 (4/17) 37.3 (28/75) NS
Etiology
   Male factor  29.4 (5/17) 14.7 (11/75) NS
   Female factor  70.6 (12/17) 60.0 (45/75) NS
   Unexplained  11.8 (2/17) 32.0 (24/75) NS
BMI (kg/m
2) 23.7±4.0 21.6±5.3 0.022
Infertility duration (yr) 2.8±2.3 3.6±2.2 NS
CA-125 (IU/mL) 21.6±16.6 19.2±14.8 NS
CA-125 ≥17 (IU/mL)       58.8 (10/17)     49.3 (37/75) NS
Number of IUI cycles 1.6±0.9 1.6±0.9 NS
HSG abnormality
a 53.8 (7/13) 34.0 (18/53) NS
Ampules of gonadotropin 12.1±8.8 6.8±6.1 0.009
Number of follicles ≥16 mm 2.1±1.1 1.6±0.9 0.036
Total motile sperm count (×10
6) 51.9±20.1 63.5±35.8 NS
EM thickness at the time of hCG  
   injection (mm)
10.8±2.3 8.3±2.4 <0.001
Values are presented as mean±SD or % (number).
NS, not significant; BMI, body mass index; HSG, hysterosalpingography; EM, 
endometrium.
aTwenty-six cases had no available HSG results.  http://dx.doi.org/10.5653/cerm.2011.38.3.164
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osis, for example, some investigators have suggested that cytokines 
and growth factors secreted by the ectopic endometrial tissue may 
interfere with ovulation, fertilization, implantation, and embryonic 
development [18]. However, in the present study, we have found no 
significant relationship between the success of IUI and the serum CA-
125 level, suggesting that the measurement of CA-125 in infertile 
patients with no history of pelvic pathology would not be valuable in 
predicting IUI outcome. It is possible that subclinical pelvic pathology 
combined with a mild elevation of CA-125 does not have a negative 
effect on the outcome of IUI. Elevation of the serum CA-125 level 
does not directly correlate to pelvic pathologies since not all of the 
patients had undertaken laparoscopic examination. Singh and col-
leagues reported that individuals diagnosed with mild adnexal ad-
hesion through laparoscopic examination did not have a significantly 
different pregnancy rate following IUI than infertility patients [16].
The pregnancy rate of IUI has been reported to range from 10 to 
14% per cycle [3,19,20]. Many factors have been demonstrated to in-
fluence the success of IUI, though there is some disagreement about 
the ranking of the factors [3,19-21]. Although the size of study popu-
lation was relatively small, we also observed results inconsistent with 
previous studies. In previous investigations, the woman’s age has been 
shown to affect the outcome of IUI, while we found no significant 
difference in the patient’s age according to outcome of IUI. In addi-
tion, the mean BMI of the pregnancy group was significantly higher 
than that of the non-pregnancy group in the present study, consis-
tent with the result of Wang et al. [22] Since conflicting data on the 
association between BMI and the success of IUI have been reported, 
this topic needs further investigation [23-25].
In this investigation, we observed that serum CA-125 level has no 
prognostic value among infertile patients without gross pelvic pa-
thology undergoing IUI cycles. Careful consideration must be given 
regarding routine measurement of serum CA-125 level in infertile 
patients with no pelvic pathology.
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